CRIS Curis Inc

Price (delayed)

$8.26

Market cap

$756.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.43

Enterprise value

$686.91M

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights
Curis's EPS has surged by 52% YoY and by 10% QoQ
CRIS's debt is down by 34% YoY and by 16% from the previous quarter
The net income is down by 14% since the previous quarter and by 9% year-on-year
CRIS's quick ratio is down by 13% since the previous quarter

Key stats

What are the main financial stats of CRIS
Market
Shares outstanding
91.6M
Market cap
$756.59M
Enterprise value
$686.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.72
Price to sales (P/S)
73.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.07
Earnings
Revenue
$10.24M
EBIT
-$34.26M
EBITDA
-$33.54M
Free cash flow
-$31.61M
Per share
EPS
-$0.43
Free cash flow per share
-$0.35
Book value per share
$1.23
Revenue per share
$0.11
TBVPS
$1.88
Balance sheet
Total assets
$181.19M
Total liabilities
$68.72M
Debt
$5.35M
Equity
$112.47M
Working capital
$148.67M
Liquidity
Debt to equity
0.05
Current ratio
19.9
Quick ratio
19.7
Net debt/EBITDA
2.08
Margins
EBITDA margin
-327.5%
Gross margin
95%
Net margin
-334.5%
Operating margin
-297.2%
Efficiency
Return on assets
-22%
Return on equity
-40.7%
Return on invested capital
-57.1%
Return on capital employed
-19.8%
Return on sales
-334.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRIS stock price

How has the Curis stock price performed over time
Intraday
-2.02%
1 week
1.72%
1 month
-1.2%
1 year
671.96%
YTD
0.85%
QTD
2.35%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$10.24M
Gross profit
$9.73M
Operating income
-$30.44M
Net income
-$34.26M
Gross margin
95%
Net margin
-334.5%
CRIS's operating margin is down by 25% year-on-year and by 22% since the previous quarter
Curis's operating income has decreased by 21% QoQ and by 15% YoY
CRIS's net margin is down by 19% YoY and by 15% from the previous quarter
The net income is down by 14% since the previous quarter and by 9% year-on-year

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
6.72
P/S
73.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
67.07
Curis's EPS has surged by 52% YoY and by 10% QoQ
The equity has contracted by 8% from the previous quarter
CRIS's price to sales (P/S) is 40% higher than its last 4 quarters average of 53.8
The revenue has declined by 9% year-on-year

Efficiency

How efficient is Curis business performance
The ROIC has soared by 91% YoY and by 26% from the previous quarter
The company's return on assets has surged by 74% YoY and by 11% QoQ
CRIS's return on equity is up by 35% since the previous quarter
Curis's return on sales has decreased by 19% YoY and by 15% QoQ

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 164% higher than its total liabilities
The current ratio has declined by 14% since the previous quarter
CRIS's quick ratio is down by 13% since the previous quarter
CRIS's debt is 95% less than its equity
The debt to equity has soared by 119% YoY
CRIS's debt is down by 34% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.